Thus, the clinical studies may be interpreted to support a dual role for KLK3 in prostate cancer, i.e., KLK3 may favor tumor development at early stages of prostate cancer and later inhibit tumor growth by its antiangiogenic activity [25]. The gene discussed is KLK3; the disease is neoplasm.